LEAP2, acting on ghrelin and growth hormone secretagogue receptor, according to a study by Hageman et al.<sup>1</sup> in this issue of <i>Cell Reports Medicine</i>, found its way toward the next target of pharmacotherapy for obesity and related diseases. This evidence concerns the gene GHSR and obesity due to melanocortin 4 receptor deficiency.